UCLA-led researchers demonstrated that enhancer-targeted CRISPR activation (eCRISPR-A) can rescue haploinsufficiency-associated gene-expression and phenotype signals in human autism models. Using dCas9-p300 to upregulate fetal-brain enhancers of CHD8 and SCN2A without DNA cutting, the team reported sustained increases in target expression specifically in mutant neurons and cerebral forebrain organoids. In CHD8-mutant organoids, the approach reduced abnormal organoid size and shifted gene-expression patterns toward wild-type profiles; in 2D cultures it increased markers of neuronal maturation. For SCN2A-mutant neurons, eCRISPR-A restored excitability toward wild-type firing levels. The work is positioned as a proof-of-concept for dosage-sensitive, enhancer-driven intervention strategies—moving gene therapy-style concepts toward more precise regulatory modulation in patient-derived systems.